补血合剂对慢性再生障碍性贫血患者造血细胞调节因子的影响

目的:研究补血合剂对慢性再生障碍性贫血患者造血细胞调节因子的影响。方法:对慢性再生障碍性贫血患者随机分组后,治疗组西药加补血合剂,对照组单纯西药治疗。抽取骨髓,对骨髓细胞分离培养,收集培养上清液和骨髓单个核细胞,用双抗夹心ELISA法测定培养上清液中造血细胞调节因子(IL-3、TNF-α、IFN-γ)的活性并比较其水平变化。结果:造血细胞调节因子水平:治疗组与对照组治疗前IL-3水平明显低于正常对照组,P<0.05,TNF-α、IFN-γ水平明显高于正常对照组,P<0.05;治疗后IL-3水平升高,与治疗前相比有显著性差异,P<0.05;治疗后TNF-α、IFN-γ水平降低,与治疗前相比有显著性差异,P<0.05。治疗后治疗组IL-3水平高于对照组,P<0.05;TNF-α、IFN-γ水平低于对照组,P<0.05;IL-3水平升高的差值与TNF-α、IFN-γ水平下降的差值,肾阳虚组均高于肾阴虚组,有显著性差异,P<0.05。结论:补血合剂能提高正调节因子IL-3的水平,降低负调节因子TNF-α、IFN-γ的水平,肾阳虚型患者的治疗效果优于肾阴虚型患者,为中药治疗慢性再生障碍性贫血的作用机制提供依据。     

Busuishengxue ranules mediate their effects upon non-severe aplastic anemia via mitogen-activated protein kinase/extracellular signal-regulated kinase pathway

OBJECTIVE：To observe the clinical efficacy of Busu- ishengxue granules on non-severe aplastic anemia（NSAA） and investigate its effect on the mitogen-ac- tivated protein kinase/extracellular signal-regulat- ed kinase（MAPK/ERK） pathway. METHODS： Sixty NSAA patients were divided equally into two groups. Subjects in the experimen- tal group were treated with Busuishengxue gran- ules, and the control group with Zaizaoshengxue tablets.The treatment course was 6 months and cu-rative efficacy was compared between the two groups as well as with 10 healthy individuals. Flow cytometry（FCM） was used to detect the intracellu- lar concentration of Ca2 ＋（[Ca2 ＋]i）. Western blotting was employed to detect the expression of enzymes in the MAPK/ERK pathway. RESULTS： The efficacy of Busuishengxue granules was significantly better than that of Zaizaoshengx- ue tablets（P0.05）. Before treatment, expression of JNK, phospho-ERK 1/2 and p-JNK was higher, and [Ca2 ＋]i higher, than that of the control group（P 0.05）. After treatment with Busuishengxue gran- ules, expression of all enzymes related to signal transduction pathways in the blood cells of NSSA patients were altered to different degrees. CONCLUSION： Busuishengxue granules had a bet- ter effect with regard to improving symptom scores, increasing the number of blood leukocytes, and increasing hemoglobin levels than Zaizaosh- engxue tablets, and they differed slightly in terms of increasing the number of platelets.     

Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia

We retrospectively investigated the incidence, risk factors, and outcomes of SOS (sinusoidal obstruction syndrome; previously veno-occlusive disease [VOD]) after allogeneic hematopoietic stem cell transplantation (alloHSCT) in aplastic anemia. Two hundred and sixty patients were included in the analysis. SOS developed in 7.3% (n = 19/260) of patients. Classical Cy (200 mg/m²)-ATG was the most common conditioning regimen (84.2%) in the SOS group. The SOS mortality rate was 4/19 (21.1%). Univariate analyses revealed that Cy 200 mg/m² conditioning (p = 0.035), classical Cy-ATG conditioning (p = 0.007), and horse ATG conditioning (p < 0.001) were significant risk factors for developing SOS. Multivariate analysis revealed that only horse ATG conditioning was a poor prognostic factor (HR = 3.484; 95% CI 1.226–9.904; p = 0.002). Rabbit ATG (HR 12.719; 95% CI 2.332–69.373; p = 0.003) and weight gain > 10% (HR 35.655; 95% CI 2.208–575.805; p = 0.012) were risk factors in the overall SOS group. Both rabbit ATG conditioning and weight gain of more than 10% were associated with poor overall survival with a median of 1.2 months (5Y survival rate, any risk factor vs. none: 74.6% vs. 0.0%; p < 0.001; Fig. 2) in the SOS group.     

Effect of intraoperative intravenous ferric derisomaltose supplementation on reduction of postoperative anemia and transfusion in chronic kidney disease patients after total knee replacement

Total knee replacement (TKR) is associated with a large amount of bleeding; therefore, the prevalence of postoperative anemia is high. In particular, patients with chronic kidney disease (CKD) are more vulnerable to postoperative anemia than are healthy individuals. Accordingly, the effect of intraoperative intravenous ferric derisomaltose (FDI) supplementation on postoperative anemia and blood transfusion volume reduction in patients with CKD was studied. Patients who underwent unilateral TKR between January 2019 and December 2020 were retrospectively reviewed. In analyzing the data, the patients fell into the CKD group (n = 85) and the non-CKD group (n = 106). Each group was divided into a group using FDI and a non-FDI group, and classified into 4 groups. The postoperative hemoglobin level for each postoperative day (POD) was determined as the primary outcome. In addition, the patient transfusion rate, volume of transfusion, and length of hospital stay were set as secondary study outcomes during the period from surgery to discharge. There was no statistically significant difference in hemoglobin levels on PODs 0, 1, 2, 7, and 14 in the CKD group. In the CKD group, the transfusion volume of the FDI group was 0.58 ± 0.91 units per person, which was statistically significantly lower than 1.28 ± 1.28 units of the non-FDI group (P = .01). In the CKD group, the transfusion rate of the FDI group was 30.2%, which was statistically significantly lower than that of the non-FDI group, which was 56.3% (P = .02). This study showed that intravenous FDI supplementation after TKR in CKD patients did not reduce postoperative anemia but was an effective and safe treatment to reduce transfusion volume and transfusion rate. There was no statistically significant difference in hemoglobin levels on POD 0, 1, 2, 7, and 14 in the non-CKD group. In the non-CKD group, the transfusion volume of the FDI group was 0.46 ± 0.88 units per person, which was lower than the 0.56 ± 0.91 units of the non-FDI group, but it was not statistically significant (P = .59). In the non-CKD group, the transfusion rate of the FDI group was 23.0%, which was lower than that of the non-FDI group, which was 31.3%, but it was not statistically significant (P = .37).     

The importance of renal function in anemic patients treated with edoxaban after orthopedic surgery in a real-world clinical setting: A retrospective study

Edoxaban (Edx) has been approved to prevent venous thromboembolism after total knee and/or hip arthroplasty in Japan. However, the risk of anemia with Edx treatment remains elusive. No risk factors for Edx-associated anemia after orthopedic surgery have been reported. This study aimed to clarify the risk of anemia associated with Edx treatment and determine the risk factors for Edx-associated anemia after orthopedic surgery with a high risk for bleeding. First, the association between Edx treatment and the incidence of anemia-related events was retrospectively investigated by pharmacovigilance analyses using data from 5769,866 reports between the first quarters of 2016 and 2020 in the Food and Drug Administration Adverse Event Reporting System and 2752,050 reports between the fourth quarters of 2011 and 2019 in the Japanese Adverse Drug Event Report. Second, 221 patients who underwent Edx treatment after total knee and/or hip arthroplasty between July 2011 and June 2012 at a single center were included in a case−control study to clarify the risk factors for anemia. Edx treatment was associated with an increased risk of anemia-related events in orthopedic patients. Reduced renal function was identified as a critical risk factor for Edx-associated anemia after orthopedic surgery. The present study indicates that renal function should be considered in the risk management of increased Edx-associated anemia after orthopedic surgery.     

Associations between different eGFR estimating equations and mortality for CVD patients: A retrospective cohort study based on the NHANES database

To assess the associations of eGFR_CKD-EPI (estimated glomerular filtration rate (eGFR) by chronic kidney disease epidemiology collaboration equation), eGFR_MDRD (eGFR by modification of diet in renal disease), and serum creatinine (scr) on the death for American people diagnosed with cardiovascular disease (CVD) respectively, and to compare the predicted performance of eGFR_CKD-EPI, eGFR_MDRD, and scr. A total of 63,078 participants who derived from the National Health and Nutrition Examination Survey (NHANES) database, were obtained in this retrospective cohort study, and collected the baseline characteristics all participants. The outcomes of our study were defined as death, and eGFR estimating equations was defined as eGFR_CKD-EPI, eGFR_MDRD, and scr. Univariate and multivariate COX analysis were performed to assess the relationship. A subgroup analysis was conducted based on whether patients had anemia. Simultaneously, we also considered the predictive value of eGFR_CKD-EPI, eGFR_MDRD, and scr in the risk of death. All patients were followed for at most 5-years. After excluded participants who did not meet the inclusion criteria and had missing information, the present study included 2419 participants ultimately, and were divided into alive group (n = 1800) and dead group (n = 619). The mortality rate for CVD patients in this study was approximately 25.59% at the end of follow-up. After adjustment for covariates, the result showed that participants with eGFR_CKD-EPI/eGFR_MDRD < 30 mL/min/1.73 m² or 30 to 45 mL/min/1.73 m² had a higher risk of mortality. Similarly, participants with scr (Q4 ≥ 1.2) were associated with the increased risk of death. Additionally, eGFR_CKD-EPI has a higher predictive value in 1-year, 3-years, and 5-years risk of death among patients with CVD than eGFR_MDRD and scr. The lower level of eGFR was associated with higher risk of death among American population diagnosed with CVD, especially for non-anemic patients. Importantly, our study also displayed that CKD-EPI-based calculation equation of eGFR (eGFR_CKD-EPI) provided for a better predictive value than eGFR_MDRD and scr in the risk of death.     

产气荚膜梭菌感染引起肝脓肿和严重溶血性贫血1例及文献复习

探讨糖尿病患者产气荚膜梭菌(Cp)感染导致肝脓肿、溶血性贫血的临床特点及诊疗经过,提高对此类患者的认识和诊治水平。分析某院2022年8月收治的1例Cp感染引起肝脓肿、溶血性贫血、血流感染、多脏器功能衰竭的糖尿病患者临床资料,结合相关文献进行回顾性分析。共检索到19篇外文文献,结合本研究1例,共纳入20例患者。男性、女性各10例,平均年龄70.7岁,合并糖尿病12例。患者临床表现缺乏特异性,所有患者均有不同程度的溶血性贫血。死亡17例(85.0%),从就诊到死亡平均时间23.84 h,其中14例(82.4%)患者在明确病原菌诊断前已死亡,11例(64.7%)患者在入院≤8 h因抢救无效死亡;存活患者仅3例,均在疾病早期得到病原学结果,2例患者早期行肝脓肿穿刺引流术,另1例患者治疗过程中肝脓肿自行破溃至肝包膜下,肿块缩小。Cp感染肝脓肿合并溶血性贫血进展迅速,早期病死率极高,故早期诊断十分重要。怀疑Cp感染时,应立即行穿刺液/血液革兰染色,或经宏基因组二代测序(mNGS)等检测手段明确病原诊断,以期通过早期调整敏感抗菌药物和清除感染病灶改变患者生存结局。     

益血生胶囊联合琥珀酸亚铁治疗妊娠贫血的疗效观察

目的 探讨益血生胶囊联合琥珀酸亚铁片治疗妊娠贫血的临床疗效.方法 选取2019年6月—2020年12月天津市第一中心医院收治的100例妊娠贫血患者,按照随机数字表法将所有患者分为对照组和治疗组,每组各50例.对照组口服琥珀酸亚铁片,200 mg/次,2次/d.治疗组在对照组基础上口服益血生胶囊,4粒/次,2次/d.两组...     

生血宁片治疗缺铁性贫血982例

目的:在Ⅱ期临床研究的基础上扩大受试者范围,增加少年、老年、孕妇及术后的缺铁性贫血病人群体,进一步观察生血宁片的疗效和不良反应。方法:将982例确诊为缺铁性贫血的病人分为成年组(2 5 4例)、老年组(2 0 5例)、孕妇组(1 5 1例)、术后组(1 30例)、少年组(70例)和儿童组(1 81例) ,各组病人均口服生血宁片0 . 5g ,tid ,疗程为4周。结果:各组病人疗效相似,非儿童组有效率为85. 9%,儿童组有效率为85. 6 %;血常规各项指标(血红蛋白浓度、平均红细胞容积和平均红细胞血红蛋白量)、血清铁含量及总铁结合力均有显著改善。除少数受试者出现轻度恶心、腹部不适外,未见其他不良反应。结论:生血宁片是治疗各年龄组尤其是青少年和孕妇缺铁性贫血有效和安全的药物。     

Giant cell hepatitis with autoimmune hemolytic anemia in a Korean infant

Giant cell hepatitis (GCH) with autoimmune hemolytic anemia (AHA) is a very rare disease characterized by early onset and severe clinical manifestations, including immune hemolytic anemia and hepatitis with cholestasis. The prognosis is poor despite aggressive immunosuppressive therapy. We report here the first case of GCH with AHA in East Asia. A 2‐month‐old boy was admitted with jaundice. Blood test indicated abnormal liver function and low hemoglobin. Direct Coombs test and several autoantibodies associated with liver disease were positive, and liver biopsy was consistent with GCH. He was treated with prednisolone and ursodeoxycholic acid, and at the time of writing was in clinical and biochemical remission after prednisolone was stopped.